The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
Open accessAbstract
Background Long-acting injectable cabotegravir (CAB LA) is a novel integrase inhibitor in advanced clinical development for HIV treatment and HIV prevention. We investigated the terminal pharmacokinetics and safety of CAB LA after final injection as part of a Phase 2 study. Methods We performed a randomized, double-blind placebo-controlled trial at 8 sites in the United States (US), sub-Saharan Africa, and Brazil. Participants, age 18–65, HIV-uninfected and at low-risk for HIV, were randomized 3:1 to CAB LA or placebo. Participants received CAB LA at one of two doses/intervals (800 mg as a split 2 × 2mL injection or 600 mg as a single 3mL injection), which were aggregated for this analysis. The current analysis includes participants who received at least one injection and examines the tail phase (time from final injection to 52–76 weeks post-final injection). The outcomes were safety and pharmacokinetics. Safety was reported as incidence rates of grade 2 or higher adverse events. The apparent terminal phase half-life (t1/2app) and time to decay of CAB drug concentration to below the lower limit of quantification (LLOQ) were estimated using non-compartmental methods. The trial was registered with ClinicalTrials.gov, number NCT02178800. This trial is completed. Findings Overall, 177 (133 CAB, 44 PBO) participants received at least one injection. Median age was 31 years, 117 (66·1%) were female, 123 (69·5%) were non-white, 93 (52·5%) were from the US. Rates of grade 2 or higher adverse events on CAB were higher in the injection phase compared to the tail phase. At one time point from 52–60 weeks and at 76 weeks after final injection, 9 (22·5%) and 4 (13·3%) of males, respectively, had detectable CAB concentrations; 52 (63·4%) and 27 (42·2%) of females had detectable CAB concentrations at those time points. The estimated median time from last injection to CAB concentration below the LLOQ was 43·7 (range 20·4–152·5) weeks for males and 67·3 (range 17·7–225·5) weeks for females. Terminal phase half-life was 32% longer for female sex at birth participants compared to male participants, and 33% longer for participants with body mass index (BMI) above vs. below the study median of 27·2 for females and 25·0 for males. Interpretation The clinical importance of the long pharmacokinetic tail, significantly longer for females compared to males, and those with higher BMI, will need to be addressed in pivotal trials of treatment and prevention. Trial Registration: ClinicalTrials NCT02178800
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Self-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Self-citationAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Self-citationMcCormack, S., Dunn, D. T., Desai, M., Dolling, D. I., Gafos, M., Gilson, R., Sullivan, A. K., Clarke, A., Reeves, I., Schembri, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00056-2 · Cited by 1,878
Cited by
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women
Landovitz, R. J., Donnell, D., Clement, M. E., Hanscom, B., Cottle, L., Coelho, L., Cabello, R., Chariyalertsak, S., Dunne, E. F., Frank, I., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101016 · Cited by 900
Self-citationGandhi, R. T., Bedimo, R., Hoy, J. F., Landovitz, R. J., Smith, D. M., Eaton, E. F., Lehmann, C., Springer, S. A., Sax, P. E., Thompson, M. A., et al. (2023) · JAMA · doi:10.1001/jama.2022.22246 · Cited by 557
Self-citation
Metadata
- Authors
- Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M. A., Eshleman, S. H., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A. R., Margolis, D., Cohen, M. S., McCauley, M., & Hendrix, C. W.
- Venue
- The Lancet HIV
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 7
- Issue
- 7
- Pages
- e472-e481
- ISSN
- 2352-3018 (ISSN-L)
- OpenAlex
- W3030616052
- Cited by
- 183
- References
- 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. https://app.cochat.ai/papers/10.1016/s2352-3018(20)30106-5
- The paper
- Landovitz, R. J., Li, S., Eron, J. J., Grinsztejn, B., Dawood, H., Liu, A. Y., Magnus, M., Hosseinipour, M. C., Panchia, R., Cottle, L., Chau, G., Richardson, P., Marzinke, M. A., Eshleman, S. H., Kofron, R., Adeyeye, A., Burns, D., Rinehart, A. R., Margolis, D., . . . Hendrix, C. W. (2020). Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(20)30106-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.